A Review of ICD Antitachycardia therapy programming with our recommended generic programming template for primary and secondary prevention
Abstract
Implantable cardioverter-defibrillator (ICD) remains the main therapeutic option in reducing sudden cardiac death . Several randomized trials and registries have shown that ICDs extend survival in patients with severely impaired left ventricular function and mild to moderate heart failure . The delivery of ICD shocks remain an important source of mortality and morbidity. They are potentially proarrhythmic if delivered inappropriately and can worsen heart failure. Shocks are also painful, cause significant anxiety and can also lead to a post-traumatic stress disorder . Inappropriate ICD shocks remain also contribute a significant burden to ICD therapies. We provide an overview of important ICD trials and evolution of anti-tachycardia therapy and identify the principles on which the programming recommendations can be based to safely minimise anti-tachycardia therapies.
Keywords
Full Text:
Subscribers OnlyReferences
Moss AJ, ZarebaW, HallWJ, etal. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ;346:877–883.
BardyGH, Lee KL, Mark DB, etal. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.
Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with non-ischemic dilated cardiomyopathy.NEnglJMed2004;350: 2151–2158.
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID)Investigators. N Engl J Med 1997;337:1576–1583
Sood N, Ruwald AC, Solomon S, et al. Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. Eur Heart J2014;35:106–115.
Powell BD, Saxon LA, BoehmerJP, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol 2013;62:1647–1649.
Sweeny MO,Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL. Differences in electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010;7:353–360.
Poole Je, Johnson GW, Hellkamp AS, etal. Prognostic importance of defibrillator shocks in patients with heart failure. N Eng J Med 2008;4:1009–1017.
Sears SF,TodaroJF,LewisTS,SotileW,ContiJB.Examiningthepsychosocial impact ofimplantablecardioverterdefibrillators:aliteraturereview.ClinCardiol1999;22:481–489.
Sears SF,MatchettM,ContiJB.EffectivemanagementofICDpatient psychosocialissuesandpatientcriticalevents.JCardiovascElectrophysiol2009;20:1297–1304.
Magyar-RussellG,ThombsBD,CaiJX,BavejaT,KuhlEA,SinghPP, MontenegroBragaBarrosoM,ArthursE,RosemanM,AminN,MarineJE, ZiegelsteinRC.Theprevalenceofanxietyanddepressioninadultswith implantablecardioverterdefibrillators:asystematicreview.JPsychosomRes 2011;71:223–231.
KadishA,DyerA,DaubertJP,etal.Prophylacticdefibrillatorimplantationin patientswithnon-ischemicdilatedcardiomyopathy.NEnglJMed2004;350: 2151–2158.
Klein RC, RaittMH,Wilkoff BL, Beckman KJ, CoromilasJ,Wyse DG, et al. Analysis of implantable cardioverter defibrillator therapy in the antiarrhythmics versus implantable defibrillators (avid) trial. J CardiovascElectrophysiol. 2003;14:940–8.
Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO et al.; PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004 Oct26;110(17):2591-6.
Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 2005 Jun 7;111(22):2898-905
Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the miracle icd trial. JAMA. 2003;289:2685–94.
Daubert JP, ZarebaW, CannomDS,McNitt S, RoseroSZ,Wang P, et al. Inappropriate implantable cardioverter-defibrillator shocks in madit ii: frequency, mechanisms, predictors, and survival impact. J Am CollCardiol. 2008;51:1357–65.
Poole JE, Johnson GW, Hellkamp AS, Anderson J, CallansDJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–17.
Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, et al. Long-term outcome after ICD andCRT implantation and influence of remote device follow-up: the altitude survival study. Circulation. 2010;122:2359–67.
van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am CollCardiol. 2011;57:556–62
. Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995;92:1651–1664.
Yabe S, Smith WM, Daubert JP, Wolf PD, Rollins DL, Ideker RE. Conduction disturbances caused by high current density electric fields. Circ Res. 1990 May;66(5):1190-203.
Hurst TM, Hinrichs M, Breidenbach C, Katz N, Waldecker B. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am CollCardiol. 1999 Aug;34(2):402-8
Sweeney MO.Antitachycardiapacingforventriculartachycardiausingimplantable cardioverterdefibrillators. PACE 2004;27:1292–1305. 18.
JosephsonME, AlmendralJM,BuxtonAE,MarchlinskiFE.Mechanismsof ventriculartachycardia.Circulation1987;75:41–47.
Fisher JD.Ventriculartachycardia:practicalandprovocativeelectrophysiology. Circulation 1978;58:1000–1001.
Jimenez-CandilJ,HernandezJ,MartinA,Ruiz-OlgadoM,HerreroJ,Ledesma C, MorinigoJ,Martin-LuengoC.Influence ofbeta-blockertherapyonanti- tachycardiapacingeffectivenessformonomorphicventriculartachycardia occurring inimplantablecardioverter-defibrillatorpatients:adosedependent effect. Europace2010;12:1231–1238
Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. 2001;104: 796–801
Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW et al. PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am CollCardiol. 2008 Aug 12;52(7):541-50
Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP et al. MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012 Dec 13;367(24):2275-83
Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JB, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: theADVANCE III randomized clinical trial. JAMA. 2013 May 8;309(18):1903-11
Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J CardiovascElectrophysiol. 2014 Jan;25(1):52-9.
Kusumoto FM, Calkins H, Boehmer J,et al.; Heart Rhythm Society; American College of Cardiology; American Heart Association. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. J Am Coll Cardiol. 2014 Sep 16;64(11):1143-77
DOI: http://dx.doi.org/10.18103/imr.v2i8.159
Refbacks
- There are currently no refbacks.